Carbon monoxide-releasing molecule-3 protects against ischemic stroke by suppressing neuroinflammation and alleviating blood-brain barrier disruption
Open Access
- 21 June 2018
- journal article
- research article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 15 (1) , 188
Abstract
At low levels, carbon monoxide (CO) has been shown to have beneficial effects on multiple organs and tissues through its potential anti-inflammatory, anti-apoptotic, and anti-proliferative properties. However, the effect of CO-releasing molecule (CORM)-3, a water-soluble CORM, on ischemic stroke and its mechanism of action are still unclear. We investigated the role of CORM-3 in the mouse model of transient middle cerebral artery occlusion (tMCAO). CORM-3 or saline was administered to mice by retro-orbital injection at the time of reperfusion after 1-h tMCAO or at 1 h after sham surgery. We assessed infarct volume and brain water content at 24 and 72 h after ischemia, blood-brain barrier permeability at 6 and 72 h after ischemia, and neurologic deficits on days 1, 3, 7, and 14. Among mice that underwent tMCAO, those that received CORM-3 had significantly smaller infarct volume and greater expression of neuronal nuclear antigen (NeuN) and microtubule-associated protein 2 than did saline-treated mice. CORM-3-treated mice had significantly fewer activated microglia in the peri-infarction zone than did control mice and exhibited downregulated expression of ionized calcium-binding adapter molecule (Iba)-1, tumor necrosis factor-α, and interleukin 1β. CORM-3-treated mice had significantly lower brain water content and enhanced neurologic outcomes on days 3, 7, and 14 post-tMCAO. Lastly, CORM-3 treatment reduced Evans blue leakage; increased expression of platelet-derived growth factor receptor-β, tight junction protein ZO-1, and matrix protein laminin; and decreased protein level of matrix metalloproteinase-9. CORM-3 treatment at the time of reperfusion reduces ischemia-reperfusion-induced brain injury by suppressing neuroinflammation and alleviating blood-brain barrier disruption. Our data suggest that CORM-3 may provide an effective therapy for ischemic stroke.Keywords
Funding Information
- National Natural Science Foundation of China (81571137, 81771247)
- the American Heart Association Grant-in-Aid (17GRNT33660766)
- Foundation for the National Institutes of Health (R01NS078026, R01AT007317, R56NS096549, R21NS101614, R21NS102899, UG3NS106937)
- Stimulating and Advancing ACCM Research (StAAR)
- National Nature Science Foundation of China (U1704166)
- Henan Province Science and Technology Cooperation Projects (No. 182106000061)
This publication has 70 references indexed in Scilit:
- MMP-9 Inhibition: a Therapeutic Strategy in Ischemic StrokeMolecular Neurobiology, 2013
- Inflammatory Cytokines in Experimental and Human StrokeJournal of Cerebral Blood Flow & Metabolism, 2012
- Carbon Monoxide–Activated Nrf2 Pathway Leads to Protection Against Permanent Focal Cerebral IschemiaStroke, 2011
- Retro-orbital injections in miceLab Animal, 2011
- Iron Toxicity in Mice with Collagenase-Induced Intracerebral HemorrhageJournal of Cerebral Blood Flow & Metabolism, 2010
- Low Doses of Carbon Monoxide Protect Against Experimental Focal Brain IschemiaNeurotoxicity Research, 2009
- Heme oxygenase-1 exacerbates early brain injury after intracerebral haemorrhageBrain, 2007
- Carbon Monoxide Signaling in Promoting Angiogenesis in Human Microvessel Endothelial CellsAntioxidants & Redox Signaling, 2005
- Water-soluble carbon monoxide-releasing molecules: helping to elucidate the vascular activity of the ‘silent killer’British Journal of Pharmacology, 2004
- Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size in vivoAmerican Journal of Physiology-Heart and Circulatory Physiology, 2004